Aeterna shares tumble after cancer-killing agent fails in Phase III trial

Shares in Aeterna Zentaris (NSDQ:AEZS) fell more than -50% this morning after the company said that the Phase III trial of Zoptrex did not meet its primary endpoint in women with locally advanced, recurrent or metastatic endometrial cancer.

The ZoptEC pivotal trial was designed to evaluate the safety and efficacy of a hybrid molecule made up of a synthetic peptide carrier and doxorubicin. Researchers randomized 512 patients to receive either Zoptrex or doxorubicin intravenously every 3 weeks for up to 9 cycles.

Get the full story at our sister site, Drug Delivery Business News.

The post Aeterna shares tumble after cancer-killing agent fails in Phase III trial appeared first on MassDevice.

from MassDevice http://ift.tt/2qvD25r